[go: up one dir, main page]

PT2776032T - Tratamento de neoplasias malignas hematológicas com um anticorpo anti cxcr4 - Google Patents

Tratamento de neoplasias malignas hematológicas com um anticorpo anti cxcr4

Info

Publication number
PT2776032T
PT2776032T PT12787343T PT12787343T PT2776032T PT 2776032 T PT2776032 T PT 2776032T PT 12787343 T PT12787343 T PT 12787343T PT 12787343 T PT12787343 T PT 12787343T PT 2776032 T PT2776032 T PT 2776032T
Authority
PT
Portugal
Prior art keywords
treatment
hematologic malignancies
cxcr4 antibody
cxcr4
antibody
Prior art date
Application number
PT12787343T
Other languages
English (en)
Inventor
R Kuhne Michelle
Pan Chin
m cardarelli Josephine
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT2776032T publication Critical patent/PT2776032T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT12787343T 2011-11-09 2012-11-09 Tratamento de neoplasias malignas hematológicas com um anticorpo anti cxcr4 PT2776032T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
PT2776032T true PT2776032T (pt) 2019-01-21

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12787343T PT2776032T (pt) 2011-11-09 2012-11-09 Tratamento de neoplasias malignas hematológicas com um anticorpo anti cxcr4

Country Status (24)

Country Link
US (2) US10428151B2 (pt)
EP (1) EP2776032B1 (pt)
JP (1) JP6541350B2 (pt)
KR (1) KR102024957B1 (pt)
CN (1) CN104039320B (pt)
AU (1) AU2012335553B2 (pt)
BR (1) BR112014011144A2 (pt)
CA (1) CA2855155A1 (pt)
CY (1) CY1121331T1 (pt)
DK (1) DK2776032T3 (pt)
EA (1) EA026153B1 (pt)
ES (1) ES2705001T3 (pt)
HR (1) HRP20182183T1 (pt)
HU (1) HUE043001T2 (pt)
IL (1) IL232517B (pt)
LT (1) LT2776032T (pt)
MX (1) MX357100B (pt)
PL (1) PL2776032T3 (pt)
PT (1) PT2776032T (pt)
RS (1) RS58102B1 (pt)
SG (1) SG11201401386XA (pt)
SI (1) SI2776032T1 (pt)
SM (1) SMT201900026T1 (pt)
WO (1) WO2013071068A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2486941T1 (sl) * 2006-10-02 2017-08-31 E. R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo CXCR4 in njihova uporaba
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
US10233248B2 (en) 2013-11-06 2019-03-19 Bristol-Myers Squibb Company Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an anti-CXCR4 antibody
WO2015085075A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
EP3079683A4 (en) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
ES2729057T3 (es) * 2013-12-17 2019-10-30 Aimm Therapeutics Bv Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos
EP3102607B1 (en) * 2014-02-06 2018-08-22 Yeda Research and Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
KR20160132031A (ko) * 2014-02-19 2016-11-16 마이크로콘스탄스 차이나 아이엔씨 케모카인 수용체 대항물질 및 그것의 병용 요법
SG11201705583XA (en) * 2015-01-09 2017-08-30 Adalta Pty Ltd Cxcr4 binding molecules
DK3283107T3 (da) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
JP2018516969A (ja) 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
EP3352800B1 (en) * 2015-09-24 2022-01-05 The University of North Carolina at Chapel Hill Methods and compositions for reducing metastases
US20180353472A1 (en) * 2015-11-09 2018-12-13 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
BR112018016924A2 (pt) * 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
WO2017189999A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
CA3025019A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
US20190175557A1 (en) * 2016-06-16 2019-06-13 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
EP3576787A4 (en) * 2017-01-31 2020-09-23 MSM Protein Technologies Inc. ANTI-CXCR4 ANTIBODY
AU2018225566B2 (en) * 2017-02-21 2019-11-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3058175A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
WO2019113456A1 (en) * 2017-12-08 2019-06-13 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
KR102693317B1 (ko) * 2018-03-13 2024-08-07 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN120943884A (zh) 2018-03-27 2025-11-14 百时美施贵宝公司 使用紫外线信号实时监测滴度
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
EP4225770A1 (en) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
US20250188152A1 (en) 2022-03-09 2025-06-12 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
TW202444754A (zh) * 2023-01-30 2024-11-16 英商凱麥博有限公司 抗體
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN119119196B (zh) * 2024-08-01 2025-09-09 青岛大学 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2117953C (en) 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
WO2005024015A1 (en) 2003-09-04 2005-03-17 Medarex, Inc. Expression vector
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
EP2029155B1 (en) 2006-02-28 2016-04-13 Pharma Mar S.A. Improved treatment of multiple myeloma
SI2486941T1 (sl) 2006-10-02 2017-08-31 E. R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo CXCR4 in njihova uporaba
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2009140124A1 (en) 2008-05-14 2009-11-19 Eli Lilly And Company Anti-cxcr4 antibodies
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2405916B1 (en) 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
WO2010135468A1 (en) 2009-05-19 2010-11-25 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
MX2013002051A (es) 2010-08-20 2013-06-28 Cerulean Pharma Inc Particulas, composiciones y conjugados de peptido terapeutico-polimero y metodos relacionados.

Also Published As

Publication number Publication date
CY1121331T1 (el) 2020-05-29
AU2012335553B2 (en) 2017-09-21
WO2013071068A2 (en) 2013-05-16
WO2013071068A3 (en) 2013-07-18
EP2776032A2 (en) 2014-09-17
ES2705001T3 (es) 2019-03-21
CA2855155A1 (en) 2013-05-16
HRP20182183T1 (hr) 2019-02-22
CN104039320B (zh) 2019-10-15
MX2014005267A (es) 2014-07-28
LT2776032T (lt) 2018-12-10
JP2014533279A (ja) 2014-12-11
HUE043001T2 (hu) 2019-07-29
SMT201900026T1 (it) 2019-05-10
US20140322208A1 (en) 2014-10-30
KR20140093945A (ko) 2014-07-29
EA026153B1 (ru) 2017-03-31
KR102024957B1 (ko) 2019-09-24
RS58102B1 (sr) 2019-02-28
US10428151B2 (en) 2019-10-01
EP2776032B1 (en) 2018-10-17
IL232517B (en) 2018-05-31
EA201490957A1 (ru) 2014-08-29
PL2776032T3 (pl) 2019-03-29
JP6541350B2 (ja) 2019-07-10
BR112014011144A2 (pt) 2017-05-16
IL232517A0 (en) 2014-06-30
SI2776032T1 (sl) 2018-12-31
US20200231683A1 (en) 2020-07-23
AU2012335553A1 (en) 2014-07-03
MX357100B (es) 2018-06-26
DK2776032T3 (en) 2019-02-04
CN104039320A (zh) 2014-09-10
SG11201401386XA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
SG11201401386XA (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
IL228738A0 (en) Antibodies for cancer treatment
IL232055B (en) Anti-1htra antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
PT2768857T (pt) Métodos para purificar anticorpos
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2717855A4 (en) PROCESSING METHODS
IL232510A0 (en) Treatment methods using an antibody against gamma interferon
EP2736330A4 (en) COMPOUNDS AND METHODS
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
EP2734234A4 (en) ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2736329A4 (en) COMPOUNDS AND METHODS
EP2798087A4 (en) CELL ANALYSIS OF ORGANIC LIQUIDS
IL226246A0 (en) Methods of treating cancer
IL228430A0 (en) Cancer treatment
EP2731429A4 (en) COMPOUNDS, METHODS OF PREPARATION AND METHODS OF USE
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201403739B (en) Methods of treatment with deferiprone
EP2785742A4 (en) ANTI-KDR ANTIBODIES AND METHOD OF USE THEREOF
IL228706A0 (en) Divided conduit and process for forming
GB201121564D0 (en) Use of antibody
IL232266A0 (en) Cancer treatment methods